Efficacy And Gene Expression Results From Eribulin Solti1007 Neoadjuvant Study

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

Andrew Seidman, MD: Efficacy Data Supporting the Use of Eribulin Mesylate

Targeted Oncology

Neoadjuvant biomarker analysis of NeoRHEA: palbociclib in ER+/HER2- BC

Gene expression assays to identify patients with breast cancer for neoadjuvant treatment

HRD, RB-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early BC

Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancer

PD-1 therapy with eribulin for triple negative MBC

Assessing the Role of 21-Gene Assays in Breast Cancer

Targeted Oncology

Kathy S. Albain: Patients with luminal A and B / HER2 negative breast cancer

The clinical impact of gene expression assays on early luminal breast cancer

Eribulin is effective in pretreated advanced breast cancer patients

infocusrx today

Eribulin’s Role in Triple-Negative Breast Cancer

Targeted Oncology

Dr. Edith Perez on Study 301 That Compared Eribulin to Capecitabine in MBC

Targeted Oncology

Genomic profiling for defining luminal subtypes

EMJ

Dr. Llombart-Cussac on Eribulin in HER2-Negative Metastatic Breast Cancer

Eribulin Treats Breast Cancer - Overview

Eribulin as Treatment for Metastatic Breast Cancer

Targeted Oncology

Exciting updates in biomarkers of response to neoadjuvant chemotherapy

Dr. Chris Twelves Compares Eribulin and Capecitabine

Andrew Seidman, MD: Main Indications for Dose Reduction With Eribulin

Targeted Oncology